Dec 04, 2013 at 12:37 | Source: Moneycontrol.com
The US FDA has said that it is concerned about Wockhardt's responses to the health regulator's queries and lab records are not in compliance with established standards. It also added that comany did not take appropriate actions to resolve defects while actual samples were used as 'trial' injections.
Dec 04, 2013 at 12:16 | Source: Moneycontrol.com
Infosys gains 0.6 percent after Bank of America Merrill Lynch maintains buy on the stock.
Nov 28, 2013 at 10:49 | Source: Moneycontrol.com
Dr Reddys has been among the best performers in the pharma sector this calendar, gaining around 33 percent so far.
Nov 27, 2013 at 17:07 | Source: CNBC-TV18
Drug-maker Wockhardt has fallen foul of the US drug regulator once again and this time, the focus is on its Chikalthana plant.
Nov 27, 2013 at 16:49 | Source: CNBC-TV18
According to Shardul Kulkarni of Angel Broking, one may see Wockhardt falling towards Rs 340-360 levels.
Nov 27, 2013 at 16:37 | Source: Moneycontrol.com
During November series, the Nifty plunged 3.81 percent and the Sensex lost 3.5 percent weighed down by financials, oil & gas and FMCG stocks.
Nov 27, 2013 at 15:00 | Source: Moneycontrol.com
The rupee is marginally higher on some inflows. Bond prices continue to rise on the back of a fall in US treasury yields and some strength in the rupee.
Nov 27, 2013 at 14:26 | Source: Moneycontrol.com
Most active shares are United Spirits (up 2 percent), Wockhardt (down 9 percent), Westlife Development (down 0.6 percent), SBI (down 1.2 percent), LIC Housing Finance (down 3 percent), ICICI Bank (down 0.6 percent), Infosys (down 0.5 percent) and Tata Motors (up 1.7 percent).
Nov 27, 2013 at 13:22 | Source: Moneycontrol.com
Wockhardt has informed that the company has received a warning letter from USFDA for its manufacturing units located at L1, Chikalthana, Aurangabad and B15, Waluj, Aurangabad. USFDA has also posted on its website an import alert on the manufacturing unit at L1, Chikalthana, Aurangabad.
Nov 27, 2013 at 13:00 | Source: Moneycontrol.com
Drug-maker Wockhardt falls foul of the US FDA once again. It's Chikalthana plant received an import notice from the US drug regulator for non-compliance with good manufacturing practices. The move is likely to cost the company over Rs 1,200 crore.